Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/182)
-
Patent number: 10485809Abstract: Polyethylene glycol (PEG)-conjugated glucocorticoid prodrugs, methods of preparation, and use for the treatment of diseases and disorders are disclosed. In particular, PEG-conjugated dexamethasone compounds and methods of using them for treating inflammatory and autoimmune diseases, including but not limited to lupus, are disclosed.Type: GrantFiled: November 12, 2016Date of Patent: November 26, 2019Assignee: Board of Regents of the University of NebraskaInventors: Dong Wang, Fang Yuan, Zhenshan Jia, Xiaobei Wang
-
Patent number: 10478505Abstract: The present invention relates to the formulation of steroids, including neurosteroids (e.g., allopregnanolone (ALP)) in edible oils to enhance their absorption when administered, e.g., orally or transmucosally to a patient.Type: GrantFiled: September 21, 2012Date of Patent: November 19, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Michael A. Rogawski
-
Patent number: 10471064Abstract: The invention provides a pharmaceutical composition for treating atopic dermatitis of a human that is induced by Herpes simplex virus (HSV), said pharmaceutical composition comprising an effective amount of 2-[(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy]ethyl-2-amino-3-methylbutanoate and an effective amount of an Anti-allergic agent.Type: GrantFiled: March 7, 2018Date of Patent: November 12, 2019Inventor: Lily Hsiao
-
Patent number: 10471086Abstract: The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease (“COPD”) but not manifesting clinical symptoms of COPD; and 2) subjects having very severe COPD. The difference in plasma levels is statistically significant for each protein. The identification of these proteins thus facilitates susceptibility detection, early disease detection, disease severity assessment, disease progression monitoring, and therapy efficacy monitoring.Type: GrantFiled: March 25, 2016Date of Patent: November 12, 2019Assignee: Temple University—Of The Commonwealth System Of Higher EducationInventors: Salim Merali, Steven G. Kelsen, Carlos A. Barrero
-
Patent number: 10441595Abstract: Disclosed herein are methods of treating fungal infections in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.Type: GrantFiled: June 25, 2015Date of Patent: October 15, 2019Assignee: BRIGHAM YOUNG UNIVERSITYInventors: Carl Genberg, Chad S. Beus, Paul B. Savage
-
Patent number: 10434107Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.Type: GrantFiled: March 29, 2018Date of Patent: October 8, 2019Assignee: ALLERGAN SALES, LLCInventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
-
Patent number: 10434108Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.Type: GrantFiled: May 23, 2018Date of Patent: October 8, 2019Assignee: ALLERGAN SALES, LLCInventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
-
Patent number: 10421772Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.Type: GrantFiled: July 10, 2017Date of Patent: September 24, 2019Assignee: Intercept Pharmaceuticals, Inc.Inventor: Roberto Pellicciari
-
Patent number: 10407462Abstract: The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases.Type: GrantFiled: May 28, 2015Date of Patent: September 10, 2019Assignee: BAR PHARMACEUTICALS S.R.L.Inventors: Angela Zampella, Stefano Fiorucci
-
Patent number: 10369159Abstract: [Problem] To provide a therapeutic agent for estrogen-dependent gynecological diseases such as endometriosis, uterine fibroids, and uterus adenomyosis. [Solution] To use an estrogen receptor ?-inhibiting ? partial agonist represented by the formula (a), a pharmaceutically-acceptable salt thereof, or a hydrate of either of the afore-mentioned, as an active ingredient.Type: GrantFiled: September 21, 2018Date of Patent: August 6, 2019Assignees: Nobelpharma Co., Ltd., National University Corporation Tottori UniversityInventors: Kenichiro Nakao, Tasuku Harada, Fuminori Taniguchi
-
Patent number: 10369160Abstract: The present invention relates to methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of the invention.Type: GrantFiled: April 11, 2017Date of Patent: August 6, 2019Assignee: Intercept Pharmaceuticals, Inc.Inventors: Antonio Moschetta, Jesus Maria Banales Asurmedi, Luis Bujanda Fernández de Pierola, María Jesús Perugorria Montiel, Oihane Erice Azparren
-
Patent number: 10344049Abstract: A compound and pharmaceutically acceptable salts thereof for treating cancer, having a structure represented by the following formula (I) or formula (II): in which X and Y each individually represent: R1, R2, R3, R4, and R5 individually represents hydrogen atom, acyl having 20 or less carbon atoms, alkyl having 20 or less carbon atoms, alkanoyl having 20 or less carbon atoms, aroyl having 20 or less carbon atoms, aryl having 20 or less carbon atoms, aralkyl having 20 or less carbon atoms, sulfonyl having 20 or less carbon atoms, phosphonyl having 20 or less carbon atoms, or haloacyl having 20 or less carbon atoms.Type: GrantFiled: December 14, 2017Date of Patent: July 9, 2019Assignee: AQUAVAN TECHNOLOGY CO., LTDInventors: Shi-Yie Cheng, Yao-Ting Wang, Kuo-Tang Tseng, Wen-Hung Chen, Hsin Ju Wang
-
Patent number: 10278977Abstract: There is provided a method of treatment of hypersomnolence comprising administering the steroidal compound 3?-ethynyl-3?-hydroxy-5?-androstan-17-one oxime, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.Type: GrantFiled: June 5, 2017Date of Patent: May 7, 2019Assignee: Umecrine Cognition ABInventors: Torbjörn Bäckström, Magnus Doverskog, Maja Johansson, Pontus Wasling
-
Patent number: 10273263Abstract: Various prodrug compounds having the general structure: Active agent—(acid)-(linker)—SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.Type: GrantFiled: August 24, 2017Date of Patent: April 30, 2019Assignee: Evestra, Inc.Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
-
Patent number: 10246481Abstract: Provided herein, inter alia, are methods for the preparation of modulators of farnesoid X receptor (FXR), and compositions and uses of the modulators of FXR.Type: GrantFiled: May 18, 2018Date of Patent: April 2, 2019Assignee: CITY OF HOPEInventors: Donna Yu, Barry Forman
-
Patent number: 10238664Abstract: Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumatic brain injury, spinal cord injury, cerebral palsy, seizures, cognitive delay, multiple sclerosis, stroke, autism, leukodystrophy, schizophrenia and bipolar disorder.Type: GrantFiled: July 9, 2015Date of Patent: March 26, 2019Assignee: Duke UniversityInventor: Eric J. Benner
-
Patent number: 10231982Abstract: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.Type: GrantFiled: July 31, 2018Date of Patent: March 19, 2019Assignee: Pop Test Oncology Limited Liability CompanyInventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
-
Patent number: 10202414Abstract: The present invention relates to processes for preparing compounds of formula I or a pharmaceutically acceptable salt or solvate thereof, wherein the dashed bond (----) at position 7 indicates that the substituent is in an ? or ? stereochemistry; R is hydrogen or hydroxy; and R1 is hydrogen or C1-C6 alkylType: GrantFiled: August 21, 2017Date of Patent: February 12, 2019Assignee: Intercept Pharmaceuticals, Inc.Inventors: Roberto Pellicciari, Antimo Gioello
-
Patent number: 10201550Abstract: Compounds are provided according to Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R6, R7, R8, and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: July 6, 2016Date of Patent: February 12, 2019Assignee: Sage Therapeutics, Inc.Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella
-
Patent number: 10156564Abstract: Among the various aspects of the present disclosure is the provision of methods of detecting biomarkers of endoplasmic reticulum (ER) stress-associated kidney diseases. Another aspect of the present disclosure provides for a method of treating an endoplasmic reticulum (ER) stress-associated kidney disease in a subject.Type: GrantFiled: July 31, 2017Date of Patent: December 18, 2018Assignee: Washington UniversityInventors: Ying Chen, Yeawon Kim
-
Patent number: 10144757Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.Type: GrantFiled: June 8, 2017Date of Patent: December 4, 2018Assignee: Kythera Biopharmaceuticals, Inc.Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
-
Patent number: 10144759Abstract: The sulfated oxysterol 5-cholesten-3?, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.Type: GrantFiled: February 12, 2016Date of Patent: December 4, 2018Assignee: VIRGINIA COMMONWEALTH UNIVERSITYInventors: Shunlin Ren, William M. Pandak
-
Patent number: 10143938Abstract: The present application relates to a method for obtaining a mixture of estrogens from the pregnant mare's urine.Type: GrantFiled: September 12, 2016Date of Patent: December 4, 2018Assignee: DR. REDDY'S LABORATORIES LTD.Inventors: Chandrashaker Akula, John Lomans, Madhukiran Tummidi, Prashant Anil Tatake
-
Patent number: 10143721Abstract: Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more polyanionic microbicides, such as carrageenans, including lambda carrageenan, as well as water-soluble metal salts and specified lectins. Also disclosed are methods for making and using the compositions.Type: GrantFiled: January 13, 2015Date of Patent: December 4, 2018Assignees: The Population Council, Inc., The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Barry R. O'Keefe, Melissa Robbiani, José A. Fernández Romero
-
Patent number: 10071108Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.Type: GrantFiled: February 19, 2018Date of Patent: September 11, 2018Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXELInventors: Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
-
Patent number: 10064876Abstract: Compositions and methods for treating addiction in a subject are disclosed. In particular, compositions and methods for treating addiction to a dopaminergic psychostimulant are disclosed. In some embodiments, addiction is treated by agonizing bile acid receptors in the subject. For example, in some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a therapeutically effective amount of a bile acid receptor agonist. In some embodiments, the method comprises surgically diverting bile acids in the subject in a manner suitable to increase circulating bile acids in the subject.Type: GrantFiled: July 25, 2016Date of Patent: September 4, 2018Assignee: Vanderbilt UniversityInventors: Aurelio Galli, Heinrich J. G. Matthies, Naji N. Abumrad, India A. Reddy, Charles Robb Flynn, Kevin Erreger
-
Patent number: 9987291Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.Type: GrantFiled: March 28, 2017Date of Patent: June 5, 2018Assignee: Kythera Biopharmaceuticals, Inc.Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
-
Patent number: 9974866Abstract: The present invention provides polymer-polypeptide conjugates comprising a poly(2-oxazoline) amphiphilic block copolymer linked to a polypeptide and methods of use thereof.Type: GrantFiled: April 7, 2011Date of Patent: May 22, 2018Assignee: Board of Regents of the University of NebraskaInventors: Alexander V. Kabanov, Jing Tong
-
Patent number: 9949986Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.Type: GrantFiled: November 11, 2016Date of Patent: April 24, 2018Assignee: Kythera Biopharmaceuticals, Inc.Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
-
Patent number: 9895380Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.Type: GrantFiled: September 10, 2014Date of Patent: February 20, 2018Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXELInventors: Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
-
Patent number: 9889101Abstract: A method for treatment of cervical or vaginal cancer and their associated dysplasia, including the steps of identifying a human cervical or vaginal cancer and/or dysplasia patient, administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amount is effective to reduce cancer and dysplasia symptoms, and observing a reduction of cancer and dysplasia symptoms in the patient.Type: GrantFiled: March 12, 2012Date of Patent: February 13, 2018Assignee: Wisconsin Alumni Research FoundationInventors: Paul F. Lambert, SangHyuk Chung
-
Patent number: 9867836Abstract: Increasing fertility in a mammal utilizes cationic steroidal antimicrobial (CSA) compounds and CSA-containing compositions. Such treatment in a mammal includes administering a formulation (e.g., lavage and/or infusion) including at least one CSA compound, or pharmaceutically acceptable salt thereof, to the reproductive structure(s) of the mammal (e.g., horse, dairy cow, human, etc.). The formulation may be applied topically as lavage and/or infusion to desired reproductive structures, such as the vagina, cervix, uterus, penis, or combinations thereof. The formulation may kill both planktonic and biofilm forms of sperm killing microbes, and may at least partially break up a microbial plaque or film located within any of the reproductive structures (e.g., the uterus).Type: GrantFiled: March 11, 2015Date of Patent: January 16, 2018Assignee: BRIGHAM YOUNG UNIVERSITYInventors: Chad S. Beus, Paul B. Savage
-
Patent number: 9770404Abstract: The present invention relates to a cosmetic composition for skin whitening and anti-aging, which contains 2 or more of collagen peptides, snake needle grass extract, and white ginseng saccharides as effective ingredients, improves skin resilience by increasing the content of collagen in the skin and suppresses the growth of melanin cells, improves skin brightness and uniformity, and alleviates skin yellowness and redness, so as to provide the effect of making the skin appear clearer and more radiant.Type: GrantFiled: November 21, 2011Date of Patent: September 26, 2017Assignee: Amorepacific CorporationInventors: Kuan Chi Hsu, Hyeon Chung Kim, Sung II Park, Youn Joon Kim, Sang Hoon Han
-
Patent number: 9763964Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.Type: GrantFiled: June 18, 2015Date of Patent: September 19, 2017Assignee: Intercept Pharmaceuticals, Inc.Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
-
Patent number: 9758503Abstract: A compound with antitumor activities is represented by formula A or formula B R1, R2, R3, and R4 are independently hydrogen, hydroxyl, alkoxy, halogen, formyl, unsubstituted or substituted alkyl, or unsubstituted or substituted cycloalkyl.Type: GrantFiled: April 17, 2017Date of Patent: September 12, 2017Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Chengyuan Liang, Danni Tian, Minyi Jia, Xuechuan Wang, Xiaolin Xie, Dezhu Zhang
-
Patent number: 9700051Abstract: The present invention relates to the use of a compound chosen from squalamine and a squalamine-analog aminosteroid compound as agent for disinfecting an inert material object, in particular for the pre-disinfection of medical, dental, diagnostic or surgical equipment. The present invention also provides an aqueous or water-soluble disinfecting composition beneficial for a use according to the invention, characterized in that as disinfecting active compound it comprises a said antibacterial and antifungal compound selected from squalamine and a said squalamine-analog aminosteroid compound and suitable excipients for a water-soluble or aqueous formulation.Type: GrantFiled: January 4, 2013Date of Patent: July 11, 2017Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE, UNIVERSITE D'AIX MARSEILLE, FONDATION MEDITERRANEE INFECTIONInventors: Jean-Michel Brunel, Didier Raoult, Jean-Marc Rolain
-
Patent number: 9683008Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.Type: GrantFiled: August 20, 2015Date of Patent: June 20, 2017Assignee: Kythera Biopharmaceuticals, Inc.Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
-
Patent number: 9670244Abstract: This invention relates, for example, to synthetic oxysterols. Also described are methods for using the compounds, including treating subjects in need thereof, and pharmaceutical compositions and kits for implementing methods of the invention.Type: GrantFiled: February 27, 2007Date of Patent: June 6, 2017Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Farhad Parhami, Michael E. Jung, Jennifer R. Dwyer, Khanhlinh Nguyen
-
Patent number: 9650409Abstract: The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.Type: GrantFiled: April 26, 2013Date of Patent: May 16, 2017Assignee: Intercept Pharmaceuticals, Inc.Inventor: Roberto Pellicciari
-
Patent number: 9636349Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.Type: GrantFiled: June 5, 2015Date of Patent: May 2, 2017Assignee: Kythera Biopharmaceuticals, Inc.Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
-
Patent number: 9603858Abstract: The present invention relates to methods of treating, preventing, or decreasing the occurrence of a condition characterized by Th2 overactivation or impaired Th1, or mitigating symptoms associated with a condition characterized by Th2 overactivation or impaired Th1, comprising orally administering to a subject in need thereof an effective amount of a composition comprising a plant stanol and/or plant stanol ester. The present invention also relates to methods of improving the health status of a subject suffering from asthma and increasing the levels of IL-10 in a subject in need thereof.Type: GrantFiled: October 5, 2011Date of Patent: March 28, 2017Assignee: RAISIO NUTRITION LTD.Inventors: Florence Brull, Ronald P. Mensink, Jogehum Plat
-
Patent number: 9561199Abstract: The present invention relates to oxaloacetate compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, Alzheimer's disease, and cancer.Type: GrantFiled: May 8, 2015Date of Patent: February 7, 2017Inventor: Alan B Cash
-
Patent number: 9540414Abstract: The invention relates to compounds of Formula A: or a salt, solvate, or hydrate thereof. The compounds of formula A are TGR5 modulators useful for the treatment of disease.Type: GrantFiled: August 1, 2014Date of Patent: January 10, 2017Assignee: Intercept Pharmaceuticals, Inc.Inventor: Roberto Pellicciari
-
Patent number: 9539203Abstract: The invention relates to a carrier for delivering agents to the posterior region of the eye, the carrier comprising a Vitamin E derivative, especially tocopherol. The carrier may also comprise a cell death marker, such as an annexin.Type: GrantFiled: December 19, 2008Date of Patent: January 10, 2017Assignee: UCL BUSINESS PLCInventors: Francesca Cordeiro, Stephen Moss
-
Patent number: 9532994Abstract: The present invention discloses agents and methods for inducing osteoblastic cellular differentiation, as well as the use of such agents and methods to treat patients to maintain bone mass, enhance bone formation and/or bone repair. Exemplary agents include oxysterols, alone or in combination with particular oxysterols, or other agents, such as bone morphogenic proteins, known to assist in bone formation. The invention further includes medicaments including oxysterols for the treatment of bone disorders and implants to facilitate bone repair.Type: GrantFiled: August 30, 2004Date of Patent: January 3, 2017Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Farhad Parhami
-
Patent number: 9522155Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.Type: GrantFiled: September 30, 2014Date of Patent: December 20, 2016Assignee: KYTHERA BIOPHARMACEUTICALS, INC.Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
-
Patent number: 9505798Abstract: Steroid compounds are disclosed that have a formula represented by the following: and wherein m, n, t, u1, u2, v1, v2, R1a, R1b, R2a, R2b, R3a, R3b, R3c, R3d, and Y are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the treatment or prevention of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.Type: GrantFiled: November 28, 2011Date of Patent: November 29, 2016Assignees: New York University, Memorial Sloan-Kettering Cancer CenterInventors: Dan R. Littman, Jun R. Huh, Nicolas Gabriel Albert Manel, Daniel A. Ryan, David Y. Gin, Mary S. Gin, Michael R. Krout
-
Patent number: 9498183Abstract: Methods and devices are disclosed that, in various embodiments and permutations and combinations of inventions, diagnose and treat Pulmonary Embolism or associated symptoms. In one series of embodiments, the invention consists of methods and devices for identifying patients whose Pulmonary Embolism or associated symptoms are caused or exacerbated, at least in part, by blockages of one or more of the patient's internal pulmonary veins. In some instances, stenoses or other flow limiting structures or lesions in the patient's affected veins are identified. Further, in some instances the nature of such lesions and whether there is a significant disruption of blood pressure, or both, is ascertained. In some embodiments, methods and devices for applying one or more therapies to the blockages in the patient's pulmonary veins are provided.Type: GrantFiled: December 29, 2011Date of Patent: November 22, 2016Assignee: Volcano CorporationInventors: Joe E. Brown, Marja Pauliina Margolis, Mary L. Gaddis
-
Patent number: 9375437Abstract: The present invention provides for progesterone containing pharmaceutical oral dosage forms, pharmaceutical kits, and related methods. In one embodiment, an oral dosage form formulated for on-going administration is provided. The oral dosage form includes an amount of progesterone and a pharmaceutically acceptable carrier. The oral dosage form is formulated such that upon single dose administration to a non-pregnant woman in follicular phase, the oral dosage form provides a serum progesterone C24h of at least 0.20 ng/mL.Type: GrantFiled: October 4, 2012Date of Patent: June 28, 2016Assignee: LIPOCINE INC.Inventors: Satish Kumar Nachaegari, Chandrashekar Giliyar, Chidambaram Nachiappan, Mahesh V. Patel, Srinivasan Venkateshwaran
-
Patent number: 9365608Abstract: This application is directed to the use of steroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.Type: GrantFiled: September 8, 2008Date of Patent: June 14, 2016Assignee: Ohr Pharmaceutical, Inc.Inventors: Michael McLane, Inez Ruiz-White, Henry Wolfe